Study S001840

A Phase 2, Randomized, Double-blind, Placebo-Controlled, Multi-center Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07724340
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 150
Start: 2026-06-19
Primary completion: 2027-02
Lead sponsor: Antag Therapeutics
Conditions: Adults With Overweight/Obesity and Type 2 Diabetes
Interventions: DRUG:AT673 low dose; DRUG:AT673 high dose; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Body weight [13 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.